Related Experiment Video

Updated: Jun 20, 2026

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer
07:59

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

Evaluation of PTEN and Mcl-1 expressions in NSCLC expressing wild-type or mutated EGFR

Zafer Cetin1, Gulay Ozbilim, Abdullah Erdogan

  • 1Department of Medical Biology and Genetics, Faculty of Medicine, Akdeniz University, Antalya, Turkey.

Medical Oncology (Northwood, London, England)
|September 19, 2009
PubMed

Insights

Elevated Mcl-1 protein and reduced PTEN expression may protect non-small-cell lung cancer cells from apoptosis, potentially impacting EGFR-targeted drug resistance. Further research could improve lung cancer treatment strategies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Epidermal growth factor receptor (EGFR) signaling pathways are crucial in lung cancer development.
  • EGFR-targeting drugs have improved non-small-cell lung cancer (NSCLC) treatment, but drug resistance remains a challenge.
  • Understanding molecular mechanisms of resistance is vital for advancing NSCLC therapy.

Purpose of the Study:

  • To investigate the roles of PTEN, Mcl-1, and EGFR in NSCLC, particularly concerning resistance to EGFR-targeting therapies.
  • To identify potential biomarkers for predicting treatment response and resistance in NSCLC patients.

Main Methods:

  • Western blot analysis to quantify PTEN, Mcl-1 (isoforms Mcl-1S and Mcl-1XL), and EGFR protein expression in 50 NSCLC samples.
  • Direct sequencing of the EGFR tyrosine kinase domain to detect mutations.
  • Correlation analysis between protein expression levels, EGFR mutations, and clinical data.

Main Results:

  • EGFR mutations (pGlu746-Ala750del) were found in 2 adenocarcinoma cases.
  • Overexpression of Mcl-1 and EGFR proteins was observed in 30% and 46% of cases, respectively.
  • Reduced PTEN expression was detected in 34% of cases, often co-occurring with EGFR overexpression (26%) and increased Mcl-1 (26%).
  • One patient with an EGFR mutation showed both increased Mcl-1 and decreased PTEN levels.

Conclusions:

  • Reduced PTEN expression and elevated Mcl-1 protein levels may contribute to intrinsic resistance against apoptosis in NSCLC cells.
  • These factors, alongside EGFR mutations, could be key indicators for improving therapeutic strategies in NSCLC.
  • Evaluating EGFR mutations with Mcl-1 and PTEN expression in larger patient cohorts may offer critical insights for personalized NSCLC treatment.

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...